Rhinovirus Infections Drug Market Report 2026

Rhinovirus Infections Drug Market Overview

• Rhinovirus Infections Drug market size has reached to $1.36 billion in 2025 • Expected to grow to $2.05 billion in 2030 at a compound annual growth rate (CAGR) of 8.6% • Growth Driver: Rising Respiratory Disorders Fueling Growth Of The Market Due To Increasing Incidence Of Respiratory Conditions • Market Trend: Innovation In Antiviral Treatments Driving Growth In The Market Due To New FDA-Approved Drugs • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Rhinovirus Infections Drug Market?

A rhinovirus infections drug is a pharmaceutical agent designed to prevent, treat, or manage infections caused by rhinoviruses, which are the primary cause of the common cold. These drugs work by inhibiting viral replication, blocking viral entry into host cells, or modulating the immune response to reduce symptom severity and infection duration. The main products for rhinovirus infection include antivirals, immunomodulators, vaccines, nasal sprays, and symptomatic treatments. Antiviral drugs target the virus to reduce the severity and duration of infection, driving market growth through pharmaceutical advancements. These drugs are administered to various patient age groups, including infants, children, adults, and the elderly, through different routes such as oral, intranasal, and injectable. They are used for indications such as common cold, asthma exacerbation, chronic obstructive pulmonary disease (COPD) exacerbation, and other conditions. Distribution channels include hospital pharmacies, retail pharmacies, online pharmacies, and specialty pharmacies.

What Is The Rhinovirus Infections Drug Market Growth Forecast?

The rhinovirus infections drug market size is expected to see strong growth in the next few years. It will grow to $2.05 billion in 2030 at a compound annual growth rate (CAGR) of 8.6%. The growth in the forecast period can be attributed to advances in antiviral research, improved viral targeting technologies, rising respiratory infection awareness, pediatric drug development, innovation in nasal delivery. Major trends in the forecast period include rising research into antiviral cold treatments, growing focus on symptom reduction therapies, expansion of nasal spray formulations, increased interest in immune-modulating drugs, shift toward preventive respiratory care.

What Is The Driver Of The Rhinovirus Infections Drug Market?

The increasing incidence of respiratory disorders is expected to propel the growth of the rhinovirus infections drug market going forward. Respiratory disorders refer to medical conditions that affect the lungs and airways, leading to difficulties in breathing, such as asthma, chronic obstructive pulmonary disease (COPD), and pneumonia. The increase in respiratory disorders is primarily due to rising air pollution and exposure to occupational hazards, leading to conditions such as asthma, COPD, and pneumonia, which are more prevalent in affected populations. Rhinovirus infections drug helps respiratory disorders by targeting viral replication, reducing inflammation, and alleviating symptoms to improve respiratory function. For instance, in June 2025, according to the Office for Health Improvement & Disparities, a UK-based government agency, in the year ending 2024, England recorded 854,922 emergency respiratory-related hospital admissions a rate of 1,428 per 100,000 people, marking a 7% rise from the previous year. Therefore, the increasing incidence of respiratory disorders drives growth in the rhinovirus infections drug industry.

Key Players In The Global Rhinovirus Infections Drug Market

Major companies operating in the rhinovirus infections drug market are Pfizer Inc., Teva Pharmaceutical Industries Ltd., Cocrystal Pharma Inc., Biota Pharmaceuticals Inc., Romark Laboratories L.C., Altamira Therapeutics Ltd., Pneumagen Ltd., AIM ImmunoTech Inc., hVIVO Services Limited, Maxwell Biosciences Inc., Altesa BioSciences Inc., Via Nova Therapeutics Inc., MetP Pharma AG, Ntvirin Pharma, GlaxoSmithKline plc, Johnson & Johnson, Sanofi S.A., Bayer AG, Cipla Limited, Reckitt Benckiser Group plc

Global Rhinovirus Infections Drug Market Trends and Insights

Major companies operating in the rhinovirus infections drug market are focusing on developing innovative products such as antiviral drugs to enhance treatment efficacy, reduce symptom severity, and accelerate recovery for patients. Antiviral drugs treat viral infections by inhibiting viral replication within the body. These drugs can manage influenza, HIV, hepatitis, and rhinovirus. Some antivirals block virus entry into host cells, while others prevent viral replication or assembly. For instance, in March 2025, Altesa BioSciences Inc., a US-based biotechnology company, received clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application for vapendavir to treat rhinovirus infections in people with COPD. Vapendavir is an oral broad-spectrum antiviral drug that prevents rhinovirus from entering human cells and replicating. It has demonstrated effectiveness against 97% of rhinoviruses and other respiratory enteroviruses. Altesa BioSciences holds exclusive global rights to develop, manufacture, and commercialize vapendavir. The drug aims to provide targeted treatment for vulnerable populations, including those with COPD and asthma.

What Are Latest Mergers And Acquisitions In The Rhinovirus Infections Drug Market?

In May 2025, Altesa BioSciences, a US-based biopharmaceutical company that offers oral antiviral drug called vapendavir for the treatment of rhinovirus infections, partnered with VirTus Respiratory Research Ltd, With this partnership, Altesa aims to generate critical proof-of-concept data on its lead antiviral candidate, vapendavir, to support progression into large-scale, late-stage clinical trials for the treatment of virus-induced respiratory exacerbations. VirTus Respiratory Research Ltd. is a U.K.-based contract research organization specializing in respiratory disease models and clinical testing.

What Defines the Rhinovirus Infections Drug Market?

The rhinovirus infections drug market consists of sales of decongestants, antihistamines, and pain relievers and fever reducers. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Rhinovirus Infections Drug Market Report 2026?

The rhinovirus infections drug market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the rhinovirus infections drug industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.